This study aimed to assess the efficacy of shock wave in reducing Chemotherapy- Induced Peripheral Neuropathy in adult and pediatric tumors patients.
Peripheral neuropathy is a serious condition characterized by symmetrical, distal damage to the peripheral nerves that may be caused by several classes of drugs, including chemotherapeutic agents. Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect estimated to occur in up to 40% of patients undergoing chemotherapy, with its incidence increasing in patients being treated with multiple agents. Pharmacists play a pivotal role in the prevention and management of CIPN by recommending evidence-based pharmacologic and nonpharmacologic strategies appropriate for the individual patient.Peripheral neuropathy (PN) is a systemic disease characterized by symmetrical, distal damage to the peripheral nerves that negatively impacts patient quality of life (QOL). Prolonged symptoms associated with PN can cause pain, interfere with functional ability (e.g., dressing, driving, house-work), and disrupt emotional health.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
80
Shockwave therapy is a multidisciplinary device used in orthopedics, physiotherapy, sports medicine, urology and veterinary medicine. Its main assets are fast pain relief and mobility restoration. Together with being a non-surgical therapy with no need for painkillers makes it an ideal therapy to speed up recovery and cure various indications causing acute or chronic pain. Shockwave is an acoustic wave which carries high energy to painful spots and myoskeletal tissues with sub-acute, sub-chronic and chronic conditions. The energy promotes regeneration and reparative processes of the bones, tendons and other soft tissues. Shockwaves are characterized by jump change in pressure, high amplitude and non-periodicity. The kinetic energy of the projectile, created by compressed air, is transferred to the transmitter at the end of the applicator and further into the tissue.
South Valley University, Faculty of Physical Therapy
Qina, Qena Governorate, Egypt
RECRUITINGMalondialdehyde (MDA) as oxidative stress marker
Malondialdehyde level in blood will be measured
Time frame: Malondialdehyde (MDA) level was assessed at day 0.
Malondialdehyde (MDA) as oxidative stress marker
Malondialdehyde level in blood will be measured
Time frame: Malondialdehyde (MDA) level will be assessed at day 90.
Interlukin 6 (IL-6) as inflammatory marker
Interlukin 6 (IL-6) level in blood will be measured
Time frame: Interlukin 6 (IL-6) level was assessed at day 0.
Interlukin 6 (IL-6) as inflammatory marker
Interlukin 6 (IL-6) level in blood will be measured
Time frame: Interlukin 6 (IL-6) level will be assessed at day 90.
Plasma Neurotensin (NT) as potential marker for neuropathic pain
Plasma Neurotensin (NT) level in blood will be measured
Time frame: Plasma Neurotensin (NT)level was assessed at day 0.
Plasma Neurotensin (NT) as potential marker for neuropathic pain
Plasma Neurotensin (NT) level in blood will be measured
Time frame: Plasma Neurotensin (NT)level will be assessed at day 90.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.